Stockreport

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cance...

Turnstone Biologics Corp.  (TSBX) 
PDF Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turns [Read more]